Anti-Angiogenesis Drug Discovery and Development

Volume 1


Atta-ur-Rahman, FRS, M. Iqbal Choudhary

DOI: 10.2174/97816080516251110101
eISBN: 978-1-60805-162-5, 2011
ISBN: 978-1-60805-648-4
ISSN: 2452-3240 (Print)
ISSN: 2210-268X (Online)

Indexed in: Scopus, EBSCO, Ulrich's Periodicals Directory.

The inhibition of angiogenesis is an effective mechanism of slowing down tumor growth and malignancies. The process of induction or pr...[view complete introduction]
US $
Buy Personal eBook
Order Library eBook
Order Printed Copy
Order PDF + Printed Copy (Special Offer)

*(Excluding Mailing and Handling)

đź”’Secure Checkout Personal information is secured with SSL technology
Download Flyer

Antiangiogenic Treatment of Hematological Tumors

- Pp. 1-11 (11)

Domenico Ribatti, Vito Longo and Angelo Vacca


Antiangiogenesis was proposed as a cancer therapy over 20 years ago and the list of compounds reported to possess antiangiogenic activity is extensive. Inhibitors are grouped as specific and non-specific, depending on whether they inhibit proliferation and/or migration of endothelial cells only or are also cytotoxic for tumor cells. Antiangiogenic therapy is applicable to a wide variety of solid and hematological tumors and there is evidence that tumors do not develop resistance to its effects due to the low mutagenic potential of endothelial cells. It is too early to predict whether antiangiogenesis will be of benefit in hematological malignancies. Strategies that target both the stromal and tumor compartments, such as combining traditional cytotoxic chemotherapy with antiangiogenic agents, may indeed have an impact on drug resistance and improve the therapeutic response. Conventional chemotherapeuticals used at very low doses, strikingly and reversibly impact on certain endothelial cell functions without nonspecific cytotoxic or necrotic damage. The use of low doses in “metronomic” chemotherapy (namely, very frequent or continuous low-dose chemotherapy) as antiangiogenic targeting strategy seem particularly effective against drug-resistant tumors, especially when combined with a secondary antiangiogenic drug. Further studies are needed to secure the comprehensive understanding and to elucidate the molecular basis of the use of these new therapeutic approaches in the treatment of hematological malignancies that actually are suboptimally treated with conventional cytotoxic therapy.

Download Free  Book Details


17th Annual Discovery on Target

Webmaster Contact: Copyright © 2019 Bentham Science